Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis-Reference-Cited by-同舟云学术

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

Published:2013-01 Issue:1 Volume:108 Page:40-47
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Nanda Kavinderjit S,Cheifetz Adam S,Moss Alan C

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg2012363.pdf

Reference51 articles.

1. An evidence-based systematic review on medical therapies for inflammatory bowel disease.;Talley;Am J Gastroenterol,2011

2. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.;Clark;Gastroenterology,2007

3. Assessing response and loss of response to biological therapies in IBD.;Yanai;Am J Gastroenterol,2011

4. Review article: causative factors and the clinical management of patients with Crohns disease who lose response to anti-TNF- therapy.;Danese;Aliment Pharmacol Ther,2011

5. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis.;Rostholder;Aliment Pharmacol Ther,2012

Cited by 306 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study;BioDrugs;2024-08-22

2. The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study;Pediatric Discovery;2024-06-25

3. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis;Digestive Diseases and Sciences;2024-06-14

4. Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts;Gastroenterology;2024-06

5. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease;Clinics and Research in Hepatology and Gastroenterology;2024-06